View Older Stories View More Recent Stories

Aug 7, 2018 04:30PM Merck’s Head of Human Resources Mirian M. Graddick-Weir to Retire; Steven C. Mizell Will Assume Role on Oct. 1
Aug 3, 2018 06:37AM AstraZeneca (AZN), Merck (MRK) Announce Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
Aug 3, 2018 06:30AM Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
Jul 31, 2018 06:38AM Eisai, Merck (MRK) Announce FDA Granted Breakthrough Therapy Designation for LENVIMA in Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/p
Jul 31, 2018 06:30AM Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA® (lenvatinib) in Combination with KEYTRUDA® (pembrolizumab) as Therapy for Previously Treated Patients with Advanced
Jul 31, 2018 05:46AM Merck (MRK), Eisai Co. Granted FDA Breakthrough Therapy Designation for LENVIMA
Jul 30, 2018 09:27PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
Jul 30, 2018 06:47AM Merck (MRK) Reports Positive Opinion from EMA for KEYTRUDA (pembrolizumab) Combination with Pemetrexed & Platinum Chemotherapy
Jul 30, 2018 06:45AM European Medicines Agency Adopts Positive Opinion for KEYTRUDA® (pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small
Jul 27, 2018 06:45AM Merck Announces Second-Quarter 2018 Financial Results
Jul 26, 2018 06:54AM Merck (MRK) Says KEYTRUDA is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Jul 26, 2018 06:45AM KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Jul 25, 2018 06:47AM Merck (MRK) Announces REPEAT/KEYTRUDA Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-048 Trial
Jul 25, 2018 06:45AM REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patient
Jul 25, 2018 05:58AM Merck (MRK) Reports Phase 3 KEYNOTE-048 Trial Investigating KEYTRUDA (pembrolizumab) Anti-PD-1 Therapy Met Primary Endpoint of OS
Jul 25, 2018 12:00AM KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose
Jul 24, 2018 12:15PM Merck Announces Fourth-Quarter 2018 Dividend
Jul 24, 2018 06:51AM Merck (MRK) Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
Jul 24, 2018 06:45AM Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
Jul 19, 2018 02:50PM Merck (MRK) Won't Increase Average Price of Portfolio by More than Inflation, Lowers Some Drug Prices
Jul 19, 2018 02:47PM Merck Reinforces Commitment to Responsible Pricing
Jul 12, 2018 08:13AM Pfenex (PFNX) Secures Milestone Payment from Merck (MRK) for Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
Jul 11, 2018 06:46AM Merck (MRK) Announces FDA Granted Priority Review to its sBLA for KEYTRUDA for Treatment of Patients with Advanced Hepatocellular Carcinoma
Jul 11, 2018 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
Jul 2, 2018 06:48AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA in Combination with Chemotherapy as First-Line Treatment for Metastatic NSCLC
Jul 2, 2018 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-S
Jul 2, 2018 06:30AM Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018
Jul 2, 2018 05:46AM UPDATE: Merck (MRK), AstraZeneca (AZN) Report Approval for LYNPARZA (olaparib) in Japan for BRCA-Mutated Metastatic Breast Cancer
Jul 2, 2018 02:00AM LYNPARZA® (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer
Jun 27, 2018 05:01PM Merck (MRK) Announces Findings from WHO-led Study of Heat-Stable Carbetocin for Preventing Excessive Bleeding After Childbirth
Jun 27, 2018 05:00PM Merck Announces Findings from WHO-led Study of Investigational Heat-Stable Carbetocin for Preventing Excessive Bleeding After Childbirth
Jun 27, 2018 07:11AM UPDATE: Merck (MRK), AstraZeneca (AZN) Report Positive Results from Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Jun 27, 2018 07:00AM REPEAT/LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Jun 27, 2018 06:45AM Merck to Hold Second-Quarter 2018 Sales and Earnings Conference Call on July 27
Jun 27, 2018 02:00AM LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Jun 25, 2018 06:31AM Merck (MRK) Says FDA Accepted sBLA for its KEYTRUDA as Adjuvant Therapy in Advanced Melanoma
Jun 25, 2018 06:30AM FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma
Jun 25, 2018 06:00AM Merck (MRK) Announces New Data from Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA (sitagliptin)
Jun 23, 2018 10:00AM Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)
Jun 13, 2018 04:07PM Merck (MRK) Announces FDA Approval of its KEYTRUDA for Treatment of Refractory or Relapsed PMBCL
Jun 13, 2018 04:06PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Jun 13, 2018 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for GARDASIL9 in Women and Men Ages 27 to 45 for Prevention of Certain HPV-Related Cancers and Diseases
Jun 13, 2018 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
Jun 12, 2018 04:07PM Merck (MRK) Announces FDA Approval of its KEYTRUDA for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer
Jun 12, 2018 04:06PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)
Jun 4, 2018 05:03PM AstraZeneca (AZN), Merck (MRK) Report LYNPARZA in Combination with Abiraterone Delayed Disease Progression in mCRPC
Jun 4, 2018 05:00PM LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer
Jun 4, 2018 08:00AM Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
Jun 4, 2018 07:46AM Merck (MRK) Says KEYTRUDA Showed Promising Anti-Tumor Activity in Patients with Advanced SCLC in Phase 2 KEYNOTE-158 Study
Jun 4, 2018 07:45AM Merck’s KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study
View More Recent Stories View Older Stories